SiBone (NASDAQ:SIBN) CFO Sells 4,665 Shares

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,665 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $18.65, for a total transaction of $87,002.25. Following the completion of the transaction, the chief financial officer owned 251,895 shares in the company, valued at approximately $4,697,841.75. This trade represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Price Performance

Shares of NASDAQ SIBN traded up $0.45 during mid-day trading on Tuesday, hitting $19.14. 499,053 shares of the stock were exchanged, compared to its average volume of 618,122. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The stock’s fifty day simple moving average is $17.15 and its two-hundred day simple moving average is $15.23. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The company has a market cap of $848.84 million, a P/E ratio of -56.29 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, analysts forecast that SiBone will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On SiBone

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of SiBone during the 1st quarter worth about $225,000. Goldman Sachs Group Inc. increased its stake in shares of SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after acquiring an additional 83,919 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of SiBone in the 1st quarter valued at about $1,818,000. Finally, Legal & General Group Plc raised its position in shares of SiBone by 16.1% in the 2nd quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after acquiring an additional 5,888 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. UBS Group boosted their price objective on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. TD Cowen raised their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Truist Financial restated a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, Weiss Ratings cut SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and an average target price of $24.17.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.